Login to Your Account

Financings Roundup

FLT3 Bid 'Astellas' Promising as Before: Ambit Raises $50M

By Randy Osborne
Staff Writer

Wednesday, November 7, 2012

At least a year shy of the next milestone payment from partner Astellas Pharma Inc., Ambit Biosciences Inc. raised $50 million from existing investors to advance quizartinib in acute myelogenous leukemia (AML).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription